Avandia :: GlaxoSmithKline response to New England Journal of Medicine Editorials
The following is GlaxoSmithKline?s [NYSE:GSK] response to editorials written in the New England Journal of Medicine (NEJM) regarding Avandia? for the treatment of type 2 diabetes.